Literature DB >> 18483707

Cost of disorders of the brain in Italy.

Maura Pugliatti1, Patrik Sobocki, Ettore Beghi, Stefano Pini, Giovanni B Cassano, A Carlo Altamura, Sara Pozzoli, Giulio Rosati.   

Abstract

The aim of this study was to estimate the cost of "brain" disorders in Italy. Country-specific prevalence and health-economic data on addiction, affective, anxiety and psychotic disorders, tumours, dementia, epilepsy, migraine/other headaches, multiple sclerosis, Parkinson's disease, stroke and head trauma were reviewed. Direct medical/non-medical and indirect costs were computed. Population-based samples and national or regional registries were used. The Italian population expected with a brain disorder was 12.4 million in 2004. The highest cost per case was for tumours and multiple sclerosis; the lowest was for anxiety disorders and migraine. Dementia (8.6 billion euros), psychotic and affective disorders (18.7 billion euros), migraine (3.5 billion euros) and stroke (3.4 billion euros) represented the highest total costs. Direct medical costs were predominant for psychiatric and neurosurgical disorders, direct non-medical costs for dementia, and indirect costs for neurological disorders. The total cost of brain disorders in Italy was 40.8 billion euros, 3% of the gross national product, and 706 euros per Italian citizen/year. This figure is however likely to be underestimated as it is based on retrospective methodology and samples of brain disorders, and does not include intangible costs.

Entities:  

Mesh:

Year:  2008        PMID: 18483707     DOI: 10.1007/s10072-008-0868-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  33 in total

Review 1.  Economic evidence in psychotic disorders: a review.

Authors:  Mickael Löthgren
Journal:  Eur J Health Econ       Date:  2004-10

Review 2.  Economic evidence in migraine and other headaches: a review.

Authors:  Jenny Berg
Journal:  Eur J Health Econ       Date:  2004-10

Review 3.  Economic evidence in affective disorders: a review.

Authors:  Mickael Löthgren
Journal:  Eur J Health Econ       Date:  2004-10

Review 4.  The epidemiology of epilepsy in Europe - a systematic review.

Authors:  L Forsgren; E Beghi; A Oun; M Sillanpää
Journal:  Eur J Neurol       Date:  2005-04       Impact factor: 6.089

Review 5.  Prevalence of dementia in the elderly in Europe.

Authors:  C Berr; J Wancata; K Ritchie
Journal:  Eur Neuropsychopharmacol       Date:  2005-08       Impact factor: 4.600

Review 6.  The epidemiology of generalized anxiety disorder in Europe.

Authors:  Roselind Lieb; Eni Becker; Carlo Altamura
Journal:  Eur Neuropsychopharmacol       Date:  2005-08       Impact factor: 4.600

Review 7.  Epidemiology of headache in Europe.

Authors:  L J Stovner; J-A Zwart; K Hagen; G M Terwindt; J Pascual
Journal:  Eur J Neurol       Date:  2006-04       Impact factor: 6.089

Review 8.  Stroke incidence and prevalence in Europe: a review of available data.

Authors:  T Truelsen; B Piechowski-Jóźwiak; R Bonita; C Mathers; J Bogousslavsky; G Boysen
Journal:  Eur J Neurol       Date:  2006-06       Impact factor: 6.089

Review 9.  Alcohol use disorders in EU countries and Norway: an overview of the epidemiology.

Authors:  Jürgen Rehm; Robin Room; Wim van den Brink; Frank Jacobi
Journal:  Eur Neuropsychopharmacol       Date:  2005-08       Impact factor: 4.600

Review 10.  [Minor head injury management in Spain: a multicenter national survey].

Authors:  M Brell; J Ibáñez
Journal:  Neurocirugia (Astur)       Date:  2001       Impact factor: 0.553

View more
  13 in total

Review 1.  A literature review of indirect costs associated with stroke.

Authors:  Heesoo Joo; Mary G George; Jing Fang; Guijing Wang
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-06-21       Impact factor: 2.136

2.  The cost effectiveness of Botox in Italian patients with chronic migraine.

Authors:  M Ruggeri
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

Review 3.  Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis.

Authors:  Alexander Konnopka; Hannah König
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

4.  Multiple sclerosis in Italy: cost-of-illness study.

Authors:  F Patti; M P Amato; M Trojano; C Solaro; A Pappalardo; V Zipoli; E Portaccio; D Paolicelli; A Paolillo; F S Mennini; A Marcellusi; C Ricci; M A Battaglia
Journal:  Neurol Sci       Date:  2011-03-16       Impact factor: 3.307

5.  A diet based on multiple functional concepts improves cognitive performance in healthy subjects.

Authors:  Anne Nilsson; Juscelino Tovar; Maria Johansson; Karl Radeborg; Inger Björck
Journal:  Nutr Metab (Lond)       Date:  2013-07-15       Impact factor: 4.169

6.  Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis.

Authors:  Francesca Pierotti; Ilaria Palla; Maarten Treur; Lara Pippo; Giuseppe Turchetti
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

Review 7.  Cost of Illness of Multiple Sclerosis - A Systematic Review.

Authors:  Olivia Ernstsson; Hanna Gyllensten; Kristina Alexanderson; Petter Tinghög; Emilie Friberg; Anders Norlund
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

8.  Self-medication for migraine: A nationwide cross-sectional study in Italy.

Authors:  Paola Brusa; Gianni Allais; Cecilia Scarinzi; Francesca Baratta; Marco Parente; Sara Rolando; Roberto Gnavi; Teresa Spadea; Giuseppe Costa; Chiara Benedetto; Massimo Mana; Mario Giaccone; Andrea Mandelli; Gian Camillo Manzoni; Gennaro Bussone
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240

9.  A Patient-Based Needs Assessment for Living Well with Parkinson Disease: Implementation via Nominal Group Technique.

Authors:  Galit Kleiner-Fisman; Pearl Gryfe; Gary Naglie
Journal:  Parkinsons Dis       Date:  2013-02-17

10.  Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus.

Authors:  Maria Lucia Specchia; Chiara de Waure; Maria Rosaria Gualano; Andrea Doria; Giuseppe Turchetti; Lara Pippo; Francesco Di Nardo; Silvio Capizzi; Chiara Cadeddu; Flavia Kheiraoui; Luca Iaccarino; Francesca Pierotti; Ilaria Palla; Maria Assunta Veneziano; Daniela Gliubizzi; Antonella Sferrazza; Nicola Nicolotti; Rolando Porcasi; Giuseppe La Torre; Maria Luisa Di Pietro; Walter Ricciardi
Journal:  Biomed Res Int       Date:  2014-08-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.